Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 3/20 | 0.33 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | NPR3 | P17342 | 1/20 | 0.31 |
| ▸ | REN | P00797 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6203226 | 1.00 | AAK1 (0.36) | AAK1HDAC4HDAC1HDAC6CTSK | |
| SCHEMBL6203221 | 1.00 | AAK1 (0.36) | AAK1HDAC4HDAC1HDAC6CTSK | |
| SCHEMBL647488 | 0.99 | AAK1 (0.37) | AAK1HDAC4HDAC1HDAC6CTSK | |
| SCHEMBL5629894 | 0.90 | AAK1 (0.36) | AAK1HDAC4HDAC1HDAC6CTSK | |
| SCHEMBL3596637 | 0.90 | AAK1 (0.36) | AAK1HDAC4HDAC1HDAC6CTSK | |
| SCHEMBL5629890 | 0.90 | AAK1 (0.36) | AAK1HDAC4HDAC1HDAC6CTSK | |
| SCHEMBL648952 | 0.82 | ALDH1A1 (0.42) | HDAC1CTSKCTSSCTSLGAA | |
| SCHEMBL27611164 | 0.82 | ALDH1A1 (0.42) | HDAC1CTSKCTSSCTSLGAA | |
| SCHEMBL25867038 | 0.79 | CHRM2 (0.38) | EPHX1 | |
| SCHEMBL646838 | 0.76 | DPP4 (0.40) | AAK1HDAC4HDAC1HDAC6CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637546-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DDP-IV) | ABBVIE INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130059873-A1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBVIE INC. | 2013-03-07 | — | — | US | disclosed |
| US-8119664-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100190822-A1 | Pharmaceutical Compositions As Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2010-07-29 | — | — | US | disclosed |
| EP-1560811-B9 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBOTT LAB (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20070265302-A1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | MADAR DAVID J | 2007-11-15 | — | — | US | disclosed |
| US-20070238753-A1 | Pharmaceutical Compositions as Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV) | MADAR DAVID J | 2007-10-11 | — | — | US | disclosed |
| US-7262207-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2007-08-28 | — | — | US | disclosed |
| EP-1560811-B1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBOTT LAB (US) | 2007-08-01 | — | — | EP | disclosed |
| US-7238724-B2 | Antidiabetic agents; hyperlipemic agents; obestity; immunomoderator; atherosclerosis | ABBOTT LABORATORIES (US) | 2007-07-03 | — | — | US | disclosed |
| US-20050215784-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2005-09-29 | — | — | US | disclosed |
| EP-1560811-A2 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | Abbott Laboratories (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20040259843-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
| US-20040121964-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES | 2004-06-24 | — | — | US | disclosed |
| WO-2004026822-A2 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059873-A1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | DPP4, DPP3, DPP7 | AAK1 2104/4885HDAC4 419/4885HDAC1 819/4885 |
| US-20070265302-A1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | DPP4, DPP3, DPP7 | AAK1 2104/4885HDAC4 419/4885HDAC1 819/4885 |
| US-20040121964-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | AAK1 2104/4885HDAC4 419/4885HDAC1 819/4885 |
| US-20100190822-A1 | Pharmaceutical Compositions As Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | AAK1 2104/4885HDAC4 419/4885HDAC1 819/4885 |
| US-20050215784-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | AAK1 2086/4885HDAC4 414/4885HDAC1 813/4885 |
| US-20070238753-A1 | Pharmaceutical Compositions as Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | AAK1 2086/4885HDAC4 414/4885HDAC1 813/4885 |
| US-20040259843-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | AAK1 2104/4885HDAC4 419/4885HDAC1 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.